An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
About the study
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347).
No study drug will be given during this study.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 [NCT05092347].
- Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
- Willing and able to comply with clinic visits and study-related procedures
- Provide informed consent signed by study patient or legally acceptable representative
EXCLUSION CRITERIA
Exclusion Criteria:
1.There are no exclusion criteria for this study.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Chronic Kidney Disease (CKD)
Age
18 - 70
Participants Needed
20
Est. Completion Date
Dec 24, 2027
Treatment Type
OBSERVATIONAL
Sponsor
Regeneron Pharmaceuticals
ClinicalTrials.gov NCT Identifier
NCT05106387
Study Number
R5459-RT-1956
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?